Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Director · Co-Chief Executive Officer | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,943,751 |
Reported balance
After 2026-09-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-30 · Exercise / conversion · Acquired 2,817 · Balance 1,943,751 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,942,323 |
Reported balance
After 2026-09-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-30 · Tax withholding · Disposed 1,428 · Balance 1,942,323 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,966,320 |
Reported balance
After 2026-10-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Acquired 23,997 · Balance 1,966,320 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,976,036 |
Reported balance
After 2026-10-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Acquired 9,716 · Balance 1,976,036 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,958,949 |
Reported balance
After 2026-10-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-10-01 · Tax withholding · Disposed 17,087 · Balance 1,958,949 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,817 |
Reported balance
After 2026-09-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-30 · Exercise / conversion · Disposed 2,817 · Balance 2,817 F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 23,998 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 23,997 · Balance 23,998 F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 48,580 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 9,716 · Balance 48,580 F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 20, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 24,623 | $164.56 | $4,051,879.62 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 18 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,992,191 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $164.365 to $165.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 29,995 | $163.91 | $4,916,465.45 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 17 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,016,814 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $163.28 to $164.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 21,882 | $162.90 | $3,564,527.47 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 16 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,046,809 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $162.28 to $163.275, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 34,584 | $161.89 | $5,598,648.13 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 15 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,068,691 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $161.28 to $162.275, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 26,243 | $160.96 | $4,223,947.31 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 14 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,103,275 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $160.25 to $161.245, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,766 | $167.81 | $631,984.89 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 13 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Eltoukhy Investments, L.P. Disclosed balance after: 365,775 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F14 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $167.40 to $168.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,908 | $166.87 | $318,395.97 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 12 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Eltoukhy Investments, L.P. Disclosed balance after: 369,541 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F13 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $166.39 to $167.385, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,819 | $165.82 | $467,449.96 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 11 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Eltoukhy Investments, L.P. Disclosed balance after: 371,449 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $165.365 to $166.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,380 | $164.58 | $720,856.46 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 10 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Eltoukhy Investments, L.P. Disclosed balance after: 374,268 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $164.365 to $165.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 8,169 | $163.86 | $1,338,562.54 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 9 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Eltoukhy Investments, L.P. Disclosed balance after: 378,648 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $163.28 to $164.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 8,174 | $162.95 | $1,331,915.70 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 8 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Eltoukhy Investments, L.P. Disclosed balance after: 386,817 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $162.28 to $163.275, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 8,755 | $161.89 | $1,417,311.93 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 7 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Eltoukhy Investments, L.P. Disclosed balance after: 394,991 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $161.28 to $162.275, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 6,557 | $160.95 | $1,055,329.48 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 6 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Eltoukhy Investments, L.P. Disclosed balance after: 403,746 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $160.25 to $161.245, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 9,285 | $161.95 | $1,503,687.18 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 5 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Eltoukhy Investments, L.P. Disclosed balance after: 410,303 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $161.67 to $162.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 21,344 | $161.07 | $3,437,918.63 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 4 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Eltoukhy Investments, L.P. Disclosed balance after: 419,588 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $160.67 to $161.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 49,841 | $160.02 | $7,975,357.46 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 3 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Eltoukhy Investments, L.P. Disclosed balance after: 440,932 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $159.67 to $160.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 12,506 | $159.16 | $1,990,481.22 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Eltoukhy Investments, L.P. Disclosed balance after: 490,773 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $158.67 to $159.655, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 10,741 | $158.22 | $1,699,467.87 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Eltoukhy Investments, L.P. Disclosed balance after: 503,279 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $157.67 to $158.665, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:59 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 700 | $160.83 | $112,581.98 |
DisclosureSEC source: 0001576280-21-000008 · wf-form4_161109353372393.xml · nonDerivative · entry 6 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Eltoukhy Investments, L.P. Disclosed balance after: 514,020 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $160.67 to $160.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:59 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,356 | $160.09 | $217,080.41 |
DisclosureSEC source: 0001576280-21-000008 · wf-form4_161109353372393.xml · nonDerivative · entry 5 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Eltoukhy Investments, L.P. Disclosed balance after: 514,720 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $159.5925 to $160.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:59 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 74,675 | $159.17 | $11,886,243.78 |
DisclosureSEC source: 0001576280-21-000008 · wf-form4_161109353372393.xml · nonDerivative · entry 4 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Eltoukhy Investments, L.P. Disclosed balance after: 516,076 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $158.59 to $159.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:59 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 38,176 | $158.04 | $6,033,147.98 |
DisclosureSEC source: 0001576280-21-000008 · wf-form4_161109353372393.xml · nonDerivative · entry 3 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Eltoukhy Investments, L.P. Disclosed balance after: 590,751 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $157.59 to $158.585, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:59 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 28,557 | $157.22 | $4,489,605.89 |
DisclosureSEC source: 0001576280-21-000008 · wf-form4_161109353372393.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Eltoukhy Investments, L.P. Disclosed balance after: 628,927 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $156.59 to $157.585, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:59 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 6,536 | $156.09 | $1,020,213.39 |
DisclosureSEC source: 0001576280-21-000008 · wf-form4_161109353372393.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Eltoukhy Investments, L.P. Disclosed balance after: 657,484 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $155.54 to $156.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 06, 2021 Filed Jan 7, 2021 21:49 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCOMMON STOCK | 279,127 | $129.54 | $36,158,111.58 |
DisclosureSEC source: 0001576280-21-000005 · wf-form4_161005616540247.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,129,518 Read SEC document |
| January 01, 2021 Filed Jan 6, 2021 01:44 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 565,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-21-000002 · wf-form4_160989742944511.xml · derivative · entry 3 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,130,382 Underlying: COMMON STOCK · 565,192 shares Expires 2027-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: One-third of the granted performance-based restricted stock units vested and converted into shares of common stock based on the Issuer's achievement of the stock price milestone, as certified by the Issuer's compensation committee on January 2, 2021. Read SEC document |
| January 01, 2021 Filed Jan 6, 2021 01:44 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 565,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-21-000002 · wf-form4_160989742944511.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,408,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 21:57 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 23,923 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001576280-20-000005 · wf-form4_160832861483079.xml · derivative · entry 3 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 735,535 Underlying: COMMON STOCK · 23,923 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 21:57 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 23,923 | $4.18 | $99,998.14 |
DisclosureSEC source: 0001576280-20-000005 · wf-form4_160832861483079.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,843,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 20:39 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 13,630 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-20-013837 · wf-form4_160080716795736.xml · derivative · entry 7 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 759,458 Underlying: COMMON STOCK · 13,630 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 20:39 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 21,078 | $103.00 | $2,171,034.00 |
DisclosureSEC source: 0001628280-20-013837 · wf-form4_160080716795736.xml · nonDerivative · entry 5 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,819,530 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 20:39 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 17,709 | $102.53 | $1,815,716.17 |
DisclosureSEC source: 0001628280-20-013837 · wf-form4_160080716795736.xml · nonDerivative · entry 4 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,840,608 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $102.00 to $102.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 20:39 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 13,834 | $101.55 | $1,404,870.37 |
DisclosureSEC source: 0001628280-20-013837 · wf-form4_160080716795736.xml · nonDerivative · entry 3 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,858,317 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $101.00 to $101.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 20:39 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 12,801 | $100.57 | $1,287,441.37 |
DisclosureSEC source: 0001628280-20-013837 · wf-form4_160080716795736.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,872,151 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $100.00 to $100.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 20:39 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 13,630 | $4.18 | $56,973.40 |
DisclosureSEC source: 0001628280-20-013837 · wf-form4_160080716795736.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,884,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 01:10 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 42,921 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-20-013721 · wf-form4_160039142031045.xml · derivative · entry 19 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 773,088 Underlying: COMMON STOCK · 42,921 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 01:10 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 48 | $102.82 | $4,935.36 |
DisclosureSEC source: 0001628280-20-013721 · wf-form4_160039142031045.xml · nonDerivative · entry 15 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,871,322 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F13 · balance_after: Includes shares previously reported as indirectly held by the Helmy A. Eltoukhy Revocable Trust. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 01:10 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 9,728 | $102.10 | $993,221.02 |
DisclosureSEC source: 0001628280-20-013721 · wf-form4_160039142031045.xml · nonDerivative · entry 14 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,871,370 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $101.71 to $102.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 01:10 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 111,591 | $100.94 | $11,264,397.27 |
DisclosureSEC source: 0001628280-20-013721 · wf-form4_160039142031045.xml · nonDerivative · entry 13 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,881,098 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $100.71 to $101.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 01:10 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 76,084 | $100.02 | $7,610,256.45 |
DisclosureSEC source: 0001628280-20-013721 · wf-form4_160039142031045.xml · nonDerivative · entry 12 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,992,689 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $99.71 to $100.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 01:10 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 8,570 | $99.16 | $849,826.05 |
DisclosureSEC source: 0001628280-20-013721 · wf-form4_160039142031045.xml · nonDerivative · entry 11 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,068,773 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $98.71 to $99.705, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 01:10 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 42,921 | $4.18 | $179,409.78 |
DisclosureSEC source: 0001628280-20-013721 · wf-form4_160039142031045.xml · nonDerivative · entry 10 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,077,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 01:10 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 45,523 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-20-013721 · wf-form4_160039142031045.xml · derivative · entry 18 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 816,009 Underlying: COMMON STOCK · 45,523 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 01:10 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 23,147 | $104.61 | $2,421,507.20 |
DisclosureSEC source: 0001628280-20-013721 · wf-form4_160039142031045.xml · nonDerivative · entry 9 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,034,422 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $104.47 to $105.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 01:10 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 152,011 | $104.07 | $15,819,222.33 |
DisclosureSEC source: 0001628280-20-013721 · wf-form4_160039142031045.xml · nonDerivative · entry 8 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,057,569 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $103.47 to $104.465, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 01:10 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 43,351 | $103.05 | $4,467,203.50 |
DisclosureSEC source: 0001628280-20-013721 · wf-form4_160039142031045.xml · nonDerivative · entry 7 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,209,580 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $102.475 to $103.465, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 01:10 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 45,523 | $4.18 | $190,286.14 |
DisclosureSEC source: 0001628280-20-013721 · wf-form4_160039142031045.xml · nonDerivative · entry 6 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,252,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2020 Filed Sep 18, 2020 01:10 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 22,926 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-20-013721 · wf-form4_160039142031045.xml · derivative · entry 17 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 861,532 Underlying: COMMON STOCK · 22,926 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| September 15, 2020 Filed Sep 18, 2020 01:10 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 683 | $104.79 | $71,569.79 |
DisclosureSEC source: 0001628280-20-013721 · wf-form4_160039142031045.xml · nonDerivative · entry 5 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,207,408 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $104.73 to $104.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 15, 2020 Filed Sep 18, 2020 01:10 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 42,106 | $104.04 | $4,380,645.08 |
DisclosureSEC source: 0001628280-20-013721 · wf-form4_160039142031045.xml · nonDerivative · entry 4 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,208,091 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $103.70 to $104.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.